RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Purchased by Barclays PLC

Barclays PLC grew its stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 277.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,729 shares of the company’s stock after acquiring an additional 29,195 shares during the quarter. Barclays PLC owned about 0.11% of RAPT Therapeutics worth $79,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Point72 Asset Management L.P. increased its position in RAPT Therapeutics by 176,725.0% during the second quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock worth $2,157,000 after purchasing an additional 706,900 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of RAPT Therapeutics by 826.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock worth $900,000 after buying an additional 263,372 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of RAPT Therapeutics by 4,183.3% during the 2nd quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock worth $1,424,000 after buying an additional 456,275 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of RAPT Therapeutics in the 2nd quarter worth $108,000. Finally, Federated Hermes Inc. boosted its holdings in RAPT Therapeutics by 188.7% in the second quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock valued at $2,428,000 after acquiring an additional 520,368 shares during the last quarter. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Wells Fargo & Company dropped their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. HC Wainwright raised shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Thursday, December 26th. Stifel Nicolaus reaffirmed a “hold” rating and set a $2.00 price target (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Finally, Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $8.00 to $2.00 in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $9.56.

RAPT Therapeutics Stock Performance

Shares of NASDAQ RAPT opened at $1.45 on Friday. RAPT Therapeutics, Inc. has a 1 year low of $0.79 and a 1 year high of $27.35. The stock’s 50-day simple moving average is $1.45 and its 200-day simple moving average is $2.07. The firm has a market cap of $50.69 million, a price-to-earnings ratio of -0.52 and a beta of 0.07.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. As a group, research analysts predict that RAPT Therapeutics, Inc. will post -2.86 EPS for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.